Literature DB >> 28259044

Neuroimmune mechanisms of behavioral alterations in a syngeneic murine model of human papilloma virus-related head and neck cancer.

Elisabeth G Vichaya1, Daniel W Vermeer2, Diana L Christian3, Jessica M Molkentine4, Kathy A Mason4, John H Lee5, Robert Dantzer3.   

Abstract

Patients with cancer often experience a high symptom burden prior to the start of treatment. As disease- and treatment-related neurotoxicities appear to be additive, targeting disease-related symptoms may attenuate overall symptom burden for cancer patients and improve the tolerability of treatment. It has been hypothesized that disease-related symptoms are a consequence of tumor-induced inflammation. We tested this hypothesis using a syngeneic heterotopic murine model of human papilloma virus (HPV)-related head and neck cancer. This model has the advantage of being mildly aggressive and not causing cachexia or weight loss. We previously showed that this tumor leads to increased IL-6, IL-1β, and TNF-α expression in the liver and increased IL-1β expression in the brain. The current study confirmed these features and demonstrated that the tumor itself exhibits high inflammatory cytokine expression (e.g., IL-6, IL-1β, and TNF-α) compared to healthy tissue. While there is a clear relationship between cytokine levels and behavioral deficits in this model, the behavioral changes are surprisingly mild. Therefore, we sought to confirm the relationship between behavior and inflammation by amplifying the effect using a low dose of lipopolysaccharide (LPS, 0.1mg/kg). In tumor-bearing mice LPS induced deficits in nest building, tail suspension, and locomotor activity approximately 24h after LPS. However, these mice did not display an exacerbation of LPS-induced weight loss, anorexia, or anhedonia. Further, while heightened serum IL-6 was observed there was minimal priming of liver or brain cytokine expression. Next we sought to inhibit tumor-induced burrowing deficits by reducing inflammation using minocycline. Minocycline (∼50mg/kg/day in drinking water) was able to attenuate tumor-induced inflammation and burrowing deficits. These data provide evidence in favor of an inflammatory-like mechanism for the behavioral alterations associated with tumor growth in a syngeneic murine model of HPV-related head and neck cancer. However, the inflammatory state and behavioral changes induced by this tumor clearly differ from other forms of inflammation-induced sickness behavior.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cytokines; Fatigue; Human papilloma virus; Inflammation; Sickness behavior

Mesh:

Substances:

Year:  2017        PMID: 28259044      PMCID: PMC5402618          DOI: 10.1016/j.psyneuen.2017.02.006

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  48 in total

1.  Fatigue in patients with prostate cancer receiving hormone therapy.

Authors:  P Stone; J Hardy; R Huddart; R A'Hern; M Richards
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

2.  Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.

Authors:  Kathryn A Mason; Hisanori Ariga; Robert Neal; David Valdecanas; Nancy Hunter; Arthur M Krieg; John K Whisnant; Luka Milas
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

3.  Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.

Authors:  J Boyette-Davis; P M Dougherty
Journal:  Exp Neurol       Date:  2011-03-05       Impact factor: 5.330

4.  Glial role in oxaliplatin-induced neuropathic pain.

Authors:  Lorenzo Di Cesare Mannelli; Alessandra Pacini; Laura Micheli; Alessia Tani; Matteo Zanardelli; Carla Ghelardini
Journal:  Exp Neurol       Date:  2014-06-23       Impact factor: 5.330

5.  Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally.

Authors:  R M Bluthé; B Michaud; K W Kelley; R Dantzer
Journal:  Neuroreport       Date:  1996-06-17       Impact factor: 1.837

6.  Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats.

Authors:  Cui-Cui Liu; Ning Lu; Yu Cui; Tao Yang; Zhi-Qi Zhao; Wen-Jun Xin; Xian-Guo Liu
Journal:  Mol Pain       Date:  2010-11-05       Impact factor: 3.395

7.  Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis.

Authors:  Theodore P Braun; Xinxia Zhu; Marek Szumowski; Gregory D Scott; Aaron J Grossberg; Peter R Levasseur; Kathryn Graham; Sheehan Khan; Sambasivarao Damaraju; William F Colmers; Vickie E Baracos; Daniel L Marks
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

8.  Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia.

Authors:  Christopher J Henry; Yan Huang; Angela Wynne; Mark Hanke; Justin Himler; Michael T Bailey; John F Sheridan; Jonathan P Godbout
Journal:  J Neuroinflammation       Date:  2008-05-13       Impact factor: 8.322

9.  Fatigue in advanced cancer: a prospective controlled cross-sectional study.

Authors:  P Stone; J Hardy; K Broadley; A J Tookman; A Kurowska; R A'Hern
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

Authors:  Joseph D Coppock; Paola D Vermeer; Daniel W Vermeer; Kimberly M Lee; W Keith Miskimins; William C Spanos; John H Lee
Journal:  Oncotarget       Date:  2016-04-26
View more
  15 in total

1.  Mammary tumor and mastectomy synergistically promote neuroinflammation in a breast cancer survivor model.

Authors:  Kathryn M Emmer; William H Walker; Ning Zhang; A Courtney DeVries
Journal:  Brain Res       Date:  2018-11-26       Impact factor: 3.252

Review 2.  The Role of Kynurenine Pathway and NAD+ Metabolism in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Mona Dehhaghi; Hamed Kazemi Shariat Panahi; Bahar Kavyani; Benjamin Heng; Vanessa Tan; Nady Braidy; Gilles J Guillemin
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

3.  Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling.

Authors:  Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

4.  Toll-like receptor 4 mediates the development of fatigue in the murine Lewis Lung Carcinoma model independently of activation of macrophages and microglia.

Authors:  Elisabeth G Vichaya; Bianca G Ford; Cana B Quave; M Raafay Rishi; Aaron J Grossberg; Robert Dantzer
Journal:  Psychoneuroendocrinology       Date:  2020-09-16       Impact factor: 4.905

5.  A Novel Syngeneic Immunocompetent Mouse Model of Head and Neck Cancer Pain Independent of Interleukin-1 Signaling.

Authors:  Matthew J Heussner; Joseph K Folger; Christina Dias; Noura Massri; Albert Dahdah; Paola D Vermeer; Geoffroy Laumet
Journal:  Anesth Analg       Date:  2021-04-01       Impact factor: 6.627

6.  Caffeine and Modafinil Ameliorate the Neuroinflammation and Anxious Behavior in Rats during Sleep Deprivation by Inhibiting the Microglia Activation.

Authors:  Meetu Wadhwa; Garima Chauhan; Koustav Roy; Surajit Sahu; Satyanarayan Deep; Vishal Jain; Krishna Kishore; Koushik Ray; Lalan Thakur; Usha Panjwani
Journal:  Front Cell Neurosci       Date:  2018-02-28       Impact factor: 5.505

Review 7.  Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments.

Authors:  Jessica C Santos; Leah M Pyter
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

Review 8.  Neuroimmunology of cancer and associated symptomology.

Authors:  Nicole N Scheff; Jami L Saloman
Journal:  Immunol Cell Biol       Date:  2021-09-12       Impact factor: 5.853

Review 9.  The High Costs of Low-Grade Inflammation: Persistent Fatigue as a Consequence of Reduced Cellular-Energy Availability and Non-adaptive Energy Expenditure.

Authors:  Tamara E Lacourt; Elisabeth G Vichaya; Gabriel S Chiu; Robert Dantzer; Cobi J Heijnen
Journal:  Front Behav Neurosci       Date:  2018-04-26       Impact factor: 3.558

Review 10.  CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.

Authors:  Gwendolyn J McGinnis; Jacob Raber
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.